NCT05272800

Brief Summary

Hemodialysis (HD) is life-sustaining in kidney failure. However, adequate fluid status depends on precise estimation of dry weight (DW), which is a goal difficult to achieve. This randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical evaluation alone. Maintenance HD patients above 18 years old were randomized to monthly clinical evaluation (CE) alone or added to twice a year BIS-guided DW estimation. Randomization was performed through random number table. Follow-up lasted up to two years. Primary outcome was survival time and secondary outcomes were rate of hospital admissions, systolic and diastolic blood pressure (BP) change and number of prescribed antihypertensive drugs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 9, 2022

Completed
Last Updated

March 24, 2022

Status Verified

March 1, 2022

Enrollment Period

2 years

First QC Date

February 28, 2022

Last Update Submit

March 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Survival

    Survival curve

    two years

Secondary Outcomes (3)

  • Hospital Admissions

    two years

  • Systolic and Diastolic Blood pressure

    two years

  • Anti-hypertensive medication

    two years

Study Arms (2)

BIS Group

EXPERIMENTAL

Dry weight is evaluated monthly by clinical examination and biannually BIS-guided.

Device: Spectroscopy Bioimpedance Analysis

CE Group

ACTIVE COMPARATOR

Dry weight is evaluated monthly by clinical examination alone.

Other: Clinical Examination alone

Interventions

Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).

Also known as: BIS
BIS Group

The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.

Also known as: CE
CE Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • CKD diagnosis,
  • years or older,
  • treated by in-center HD for longer than three months,
  • HD treatment in the Dialysis and Transplantation unit of a Brazilian University Hospital.

You may not qualify if:

  • less than thrice a week HD session,
  • lower limbs amputation,
  • pregnancy,
  • pacemaker, implantable cardioverter-defibrillator or orthopedic protheses use.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitário São Francisco de Paula

Pelotas, Rio Grande do Sul, 96020-260, Brazil

Location

Related Publications (1)

  • Stigger K, Ribeiro LR, Cordeiro FM, Bohlke M. Incidence of hospital admissions in bioimpedance-guided fluid management among maintenance hemodialysis patients-Results of a randomized controlled trial. Hemodial Int. 2023 Jul;27(3):318-325. doi: 10.1111/hdi.13076. Epub 2023 Apr 17.

MeSH Terms

Conditions

Renal Insufficiency

Interventions

Restraint, Physical

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Behavior ControlTherapeuticsImmobilizationInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: A randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical evaluation alone.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 28, 2022

First Posted

March 9, 2022

Study Start

September 1, 2019

Primary Completion

September 1, 2021

Study Completion

September 1, 2021

Last Updated

March 24, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will share

After publication, include data in a data repository (Harvard Dataverse)

Shared Documents
STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
Time Frame
After conclusion of publication process
Access Criteria
Public
More information

Locations